Beijing Stock Exchange's first 2025 annual report released

LightningPacketLoss · 2026-03-06T18:53:11+00:00

Jiangsu Deyuan Pharmaceutical released its 2025 annual report on March 5, becoming the first company listed on the Beijing Stock Exchange to publish its annual report. The report shows that in 2022, the company's operating revenue was 1.058 billion yuan, a year-on-year increase of 21.80%; net profit reached 237 million yuan, a year-on-year increase of 33.87%. The performance growth is attributed to continuous sales expansion and internal management optimization.

LightningPacketLoss

2026-03-06 18:53:11

Abstract generation in progress

This newspaper report (Reporter Meng Ke) on March 5th, Beijing Stock Exchange-listed company Jiangsu Deyuan Pharmaceutical Co., Ltd. (referred to as “Deyuan Pharmaceutical”) released its 2025 annual report, becoming the first listed company on the Beijing Stock Exchange to publish its annual report this year.

Deyuan Pharmaceutical’s annual report shows that the company achieved operating revenue of 1.058 billion yuan last year, a year-on-year increase of 21.80%; net profit of 237 million yuan, a year-on-year increase of 33.87%. The main reasons for the company’s growth in operating performance during the reporting period are: the company has always adhered to a marketing-first business philosophy, continuously strengthened its sales foundation, fully promoted market development, and achieved steady growth in sales of its products. The company continuously enhances internal operational management, optimizes personnel structure, strictly controls expenses, reduces costs and increases efficiency, and comprehensively improves overall profitability and operational quality.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes